Trustee for Ascentage Pharma (AAPG) 2022 RSU Scheme buys 50,000 shares

Rhea-AI Filing Summary

Ascentage Pharma Group International reported that the trustee of its 2022 restricted share unit (RSU) scheme bought existing shares on the market for incentive purposes. On May 28, 2026, the trustee purchased 50,000 Shares, equal to approximately 0.0134% of issued share capital.

The total consideration for these Purchased Shares was HK$1,909,800, or an average of approximately HK$38.196 per Share. Following this transaction, the trustee holds 2,315,000 existing Shares for the 2022 RSU Scheme, and will not exercise voting rights attached to shares it holds on trust.

Key Figures

Purchased Shares: 50,000 Shares Purchase as % of issued Shares: Approximately 0.0134% Total consideration: HK$1,909,800 +3 more

6 metrics

Purchased Shares 50,000 Shares Total number of existing Shares bought on May 28, 2026

Purchase as % of issued Shares Approximately 0.0134% Proportion of Purchased Shares to total issued Shares as of announcement date

Total consideration HK$1,909,800 Aggregate consideration for the 50,000 Purchased Shares, excluding related expenses

Average price per share Approximately HK$38.196 Average consideration per Purchased Share, excluding related expenses

Total shares held by trustee 2,315,000 Shares Existing Shares held by trustee for the 2022 RSU Scheme after this purchase

Announcement date May 28, 2026 Date of voluntary announcement and purchase transaction

Key Terms

2022 RSU Scheme, Trustee, on-market, voluntary announcement, +1 more

5 terms

2022 RSU Scheme financial

"for the purpose of the 2022 RSU Scheme to satisfy the RSUs upon vesting"

Trustee financial

"On May 28, 2026, the Trustee purchased a total of 50,000 existing Shares"

A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.

on-market financial

"the Trustee purchased a total of 50,000 existing Shares on-market for the purpose of the 2022 RSU Scheme"

On-market describes buying or selling shares directly through a public stock exchange at the current market price, rather than by a private or negotiated deal. Like buying an item from a store at the posted price instead of haggling privately, on-market trades happen quickly, are visible to other investors, and can move the stock price, so they affect liquidity and provide a transparent signal about supply and demand.

voluntary announcement regulatory

"This announcement is made by Ascentage Pharma Group International (the “Company”) on a voluntary basis."

restricted share unit (RSU) financial

"for the purpose of the 2022 RSU Scheme to satisfy the RSUs upon vesting"

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of May 2026

Commission File Number: 001-42484

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐ 

EXPLANATORY NOTE

On May 28, 2026, Ascentage Pharma Group International issued an announcement entitled “Purchase of Shares by the Trustee for the Purpose of the 2022 RSU Scheme”. A copy of the press release is furnished as Exhibit 99.1.

1

INDEX TO EXHIBITS

Exhibit
Number		Exhibit Title
99.1		Announcement dated May 28, 2026

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ASCENTAGE PHARMA GROUP INTERNATIONAL
Date: May 28, 2026	/s/ Dajun Yang
	Name:	Dajun Yang
	Title:	Chief Executive Officer

3

Exhibit 99.1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

VOLUNTARY ANNOUNCEMENT

PURCHASE OF SHARES BY THE TRUSTEE

FOR THE PURPOSE OF THE 2022 RSU SCHEME

This announcement is made by Ascentage Pharma Group International (the “Company”) on a voluntary basis. Reference is made to the announcements of the Company dated June 23, 2022, July 14, 2022, October 21, 2022, October 25, 2022, October 26, 2022, October 27, 2022, October 28, 2022, October 31, 2022, May 8, 2023, November 13, 2023, November 14, 2023, November 16, 2023, February 2, 2024, September 2, 2024, October 25, 2024, March 31, 2025, April 8, 2025, April 30, 2025, June 27, 2025, November 27, 2025, December 30, 2025, April 20, 2026, April 30, 2026 and May 27, 2026 (the “Announcements”) in relation to, among other things, (i) the adoption of and amendments to the 2022 RSU Scheme; (ii) the initial grant and the further grants of the 2022 Awards thereunder; and (iii) the purchase of existing Shares by the Trustee on-market for the purpose of the 2022 RSU Scheme. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

On May 28, 2026, the Trustee purchased a total of 50,000 existing Shares (the “Purchased Shares”) on-market for the purpose of the 2022 RSU Scheme to satisfy the RSUs upon vesting. Details of the Purchased Shares and the latest information about the Shares held by the Trustee under the Scheme are as follows:

Purchase date	:	May 28, 2026
Total number of the Purchased Shares	:	50,000 Shares
Percentage of the Purchased Shares to the total number of issued Shares as at the date of this announcement	:	Approximately 0.0134%
Total consideration paid for the Purchased Shares (excluding all related expenses, transaction levy, brokerage, tax, duties and levies)	:	HK$1,909,800
Average consideration per Purchased Share (excluding all related expenses, transaction levy, brokerage, tax, duties and levies)	:	Approximately HK$38.196
Total number of existing Shares purchased by the Trustee on-market for the purpose of the 2022 RSU Scheme immediately after the aforesaid purchases	:	2,315,000 Shares

The Purchased Shares are currently held by the Trustee in accordance with the 2022 RSU Scheme Rules and the terms of the trust deed entered into between the Company and the Trustee. The Trustee shall not exercise the voting rights attached to the Shares held on trust by it. As at the date of this announcement, no further grant of Awards has been made pursuant to the 2022 RSU Scheme apart from the initial grant of the 2022 Awards on June 23, 2022 and the further grants of the 2022 Awards on May 4, 2023, September 2, 2024, June 27, 2025, November 26, 2025 and April 20, 2026 as disclosed in the Announcements.

By Order of the Board

Ascentage Pharma Group International Dr.

Yang Dajun

Chairman and Executive Director

Suzhou, People’s Republic of China, May 28, 2026

As at the date of this announcement, the Board comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon Dazhong^{Note 1} as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky^{Note 2}, Ms. Marina S. Bozilenko, Dr. Debra Yu and Dr. Marc E. Lippman, MD as independent non-executive Directors.

Notes:

1. Dr. Lu Simon Dazhong satisfy the independence requirements of the U.S. Securities and Exchange Commission and Nasdaq corporate governance requirements.

2. Dr. David Sidransky is the Lead Independent Non-Executive Director of the Company.

FAQ

What did Ascentage Pharma Group International (AAPG) announce in this Form 6-K?

Ascentage Pharma Group International announced that the trustee of its 2022 RSU Scheme purchased existing shares on-market. The transaction is intended to provide shares to satisfy restricted share units when they vest under the company’s long-term incentive plan.

How many Ascentage Pharma (AAPG) shares did the trustee purchase for the 2022 RSU Scheme?

The trustee purchased a total of 50,000 existing Shares on-market for the 2022 RSU Scheme. This amount represents approximately 0.0134% of the company’s total issued shares as of the announcement date, indicating a relatively small-scale transaction.

What price did the Ascentage Pharma (AAPG) trustee pay for the purchased shares?

The trustee paid total consideration of HK$1,909,800 for the 50,000 Purchased Shares, excluding related costs. This equates to an average consideration of approximately HK$38.196 per Purchased Share, based on on-market transactions conducted on May 28, 2026.

How many Ascentage Pharma (AAPG) shares does the trustee now hold for the 2022 RSU Scheme?

Immediately after this purchase, the trustee held 2,315,000 existing Shares on-market for the purposes of the 2022 RSU Scheme. These shares are reserved to satisfy RSUs upon vesting, under the scheme rules and the related trust deed.

Will the Ascentage Pharma (AAPG) trustee vote the shares held for the 2022 RSU Scheme?

The trustee will not exercise the voting rights attached to the shares it holds under the 2022 RSU Scheme. Those shares are held on trust in accordance with the scheme rules and the trust deed between Ascentage Pharma and the trustee.

Has Ascentage Pharma (AAPG) made any new RSU grants under the 2022 Scheme?

As of this announcement, Ascentage Pharma had made no further RSU grants beyond those already disclosed. Existing grants include the initial 2022 Awards on June 23, 2022 and further grants on several later dates listed in prior company announcements.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 ANNOUNCEMENT DATED MAY 28, 2026 13.9 KB